Wuhan Huoshenshan Hospital Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Wuhan China (2020)

Organization Overview

First Clinical Trial
2020
NCT04252118
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Huoshenshan Hospital | Wuhan Huoshenshan Hospital, Wuhan, China

Active Ingredients

Drugs in Phase 4 Trials (2)

danoprevir (1 trial)

ritonavir (Norvir) (1 trial)

Drugs in Phase 2 Trials (2)

albumin (Human) (Plasbumin) (1 trial)

autologous mesenchymal stem cells (1 trial)

Drugs in Phase 1 Trials (1)

umbilical cord mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 2)

Infections (Phase 4)

Pneumonia (Phase 1)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5